Mesodermal transcription factor that plays a key role in somitogenesis and is specifically required for sclerotome development. Required for maintenance of the sclerotome polarity and formation of the cranio-cervical joints (PubMed:23290072, PubMed:24073994). Binds specifically to the promoter of target genes and regulates their expression. Activates expression of NKX3-2 in the sclerotome. Activates expression of CDKN1A and CDKN2A in endothelial cells, acting as a regulator of vascular cell proliferation. While it activates CDKN1A in a DNA-dependent manner, it activates CDKN2A in a DNA-independent manner. Required for hematopoietic stem cell (HSCs) induction via its role in somitogenesis: specification of HSCs occurs via the deployment of a specific endothelial precursor population, which arises within a sub-compartment of the somite named endotome.
Involvement in disease
Klippel-Feil syndrome 2, autosomal recessive
Contains 1 homeobox DNA-binding domain.
Nucleus. Cytoplasm. Localizes predominantly in the nucleus.
Immunofluorescence - Anti-MOX1 antibody - Aminoterminal end (ab75895)
Immunofluorescence of HeLa cells labelling MOX1 with ab75895. Hela cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with ab75895 (1:25, 1 h at 37℃). Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used as the secondary antibody (1:400, 50 min at 37℃) and cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7units/ml, 1 h at 37℃). Nuclei were counterstained with DAPI (blue) (10 µg/ml, 10 min). MOX1 immunoreactivity is localised to the nucleolus.
Western blot - MOX1 antibody - Aminoterminal end (ab75895)
Anti-MOX1 antibody (ab75895) at 1/230 dilution + 293 cell line lysate at 35 µg
Predicted band size: 28 kDa Observed band size: 28 kDa